Skip to content
Optimark(gadoversetamide)
Optimark (gadoversetamide) is a small molecule pharmaceutical. Gadoversetamide was first approved as Optimark on 1999-12-08. It has been approved in Europe to treat magnetic resonance imaging.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
diagnosisD003933
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadoversetamide
Tradename
Company
Number
Date
Products
OPTIMARKLiebel-FlarsheimN-020937 DISCN1999-12-08
4 products, RLD
OPTIMARKLiebel-FlarsheimN-020975 DISCN1999-12-08
1 products, RLD
OPTIMARK IN PLASTIC CONTAINERLiebel-FlarsheimN-020976 DISCN1999-12-08
4 products, RLD
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
V08: Contrast media
V08C: Magnetic resonance imaging contrast media
V08CA: Paramagnetic contrast media
V08CA06: Gadoversetamide
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C61112126
Magnetic resonance imagingD008279224
Brain neoplasmsD001932EFO_0003833C711113
Breast diseasesD001941N60-N65112
Brain diseasesD001927HP_0001298G93.40112
Coronary artery diseaseD003324I25.1112
Lymphatic metastasisD008207EFO_1001364112
CognitionD003071EFO_000392511
Nephrogenic fibrosing dermopathyD054989EFO_100181411
Liver neoplasmsD008113EFO_1001513C22.011
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749C6711113
Breast neoplasmsD001943EFO_0003869C501113
Cerebral arterial diseasesD002539EFO_100085922
ProstatectomyD01146811
Neoplasm metastasisD009362EFO_000970811
Central nervous system diseasesD002493HP_0002011G96.911
Retinal diseasesD012164HP_0000479H35.911
Renal artery obstructionD012078EFO_1001150N28.011
Rectal neoplasmsD01200411
Aortic aneurysmD001014EFO_0001666I71.9111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Uterine cervical neoplasmsD002583222
Hip fracturesD006620EFO_0003964S72.00112
Local anesthesiaD000772112
Uterine neoplasmsD014594EFO_0003859C55111
Postoperative painD010149G89.1811
Renal cell carcinomaD002292111
Endometrial neoplasmsD016889EFO_0004230111
Small cell carcinomaD018288111
Squamous cell carcinoma of head and neckD000077195111
Interstitial lung diseasesD017563EFO_0004244J84.8911
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I5011
Left ventricular hypertrophyD017379EFO_000389611
Myocardial infarctionD009203EFO_0000612I2111
PainD010146EFO_0003843R5211
Chronic kidney failureD007676EFO_0003884N18.611
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Takotsubo cardiomyopathyD054549EFO_1002000I51.8111
Male breast neoplasmsD01856711
Autoimmune diseasesD001327EFO_0000540M30-M3611
Aortic dissectionD000784I71.011
Aortic diseasesD00101811
AtherosclerosisD050197EFO_0003914I25.111
Intermittent claudicationD007383EFO_0003876I73.911
CardiomyopathiesD009202EFO_0000318I4211
Drug-related side effects and adverse reactionsD064420T88.711
HypersensitivityD006967EFO_0003785T78.4011
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGADOVERSETAMIDE
INNgadoversetamide
Description
Gadoversetamide is a gadolinium coordination entity that consists of Gd(3+) coordinated to 3,6,9-triazaundecadiamide in which each of the amide nitrogens is substituted by a 2-methoxyethyl group and in which the nitrogens at positions 3, 6, and 9 are each substituted by carboxylatomethyl group. The gadolinium is coordinated to the three tertiary amino groups as well as to the carboxylate groups. A white odourless powder that is freely soluble in water, gadoversetamide has paramagnetic properties and is used as a contrast agent in magnetic resonance imaging. It distributes mainly in extracellular fluid, but does not cross the blood-brain barrier. It is used particularly in imaging the brain, spine and liver. It has a role as a MRI contrast agent.
Classification
Small molecule
Drug classgadolinium derivatives (principally for diagnostic use)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-].[Gd+3]
Identifiers
PDB
CAS-ID131069-91-5
RxCUI228833
ChEMBL IDCHEMBL1200457
ChEBI ID31644
PubChem CID444013
DrugBankDB00538
UNII IDRLM74T3Z9D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 427 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,316 adverse events reported
View more details